公开(公告)号：US11833512B2

公开(公告)日：2023-12-05

申请号：US17215900

申请日：2021-03-29

Applicant: EMULATE, Inc.

Inventor： S. Jordan Kerns ,  Riccardo Barrile ,  Geraldine Hamilton ,  Catherine Karalis ,  Daniel Levner ,  Carolina Lucchesi ,  Antonio Varone ,  Remi Villenave

IPC: B01L3/00 ,  C12M1/00 ,  C12M3/06 ,  C12M1/42 ,  G01N33/50 ,  C12N5/00

CPC classification number: B01L3/502753 ,  B01L3/502715 ,  C12M23/16 ,  C12M29/04 ,  C12M35/08 ,  G01N33/5044 ,  C12N5/0018 ,  C12N5/0075

Abstract: An in vitro microfluidic “organ-on-chip” is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and the associated tissue specific epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory tissue, e.g., autoimmune disorders involving epithelia and diseases involving epithelial layers. These multicellular, layered microfluidic “organ-on-chip”, e.g. “epithelia-on-chip” further allow for comparisons between types of epithelia tissues, e.g., lung (Lung-On-Chip), bronchial (Airway-On-Chip), skin (Skin-On-Chip), cervix (Cervix-On-Chip), blood brain barrier (BBB-On-Chip), etc., in additional to neurovascular tissue, (Brain-On-Chip), and between different disease states of tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic “organ-on-chips” allow identification of cells and cellular derived factors driving disease states in addition to drug testing for reducing inflammation effecting epithelial regions.

公开(公告)号：US11248203B2

公开(公告)日：2022-02-15

申请号：US17160617

申请日：2021-01-28

Applicant: EMULATE, INC.

Inventor： Daniel Levner ,  Christopher David Hinojosa ,  Norman Wen ,  Antonio Varone ,  Justin Nguyen ,  Lina Williamson ,  S. Jordan Kerns ,  Catherine Karalis ,  Geraldine Hamilton ,  Carol Lucchesi

IPC: C12M3/06 ,  C12M1/12 ,  C12M1/00 ,  C12M1/42 ,  G01N33/50 ,  G01N33/543 ,  C12N5/0793 ,  C12N5/079 ,  C12N5/071 ,  C12N5/077

Abstract: A microfluidic device is contemplated comprising an open-top cavity with structural anchors on the vertical wall surfaces that serve to prevent gel shrinkage-induced delamination, a porous membrane (optionally stretchable) positioned in the middle over a microfluidic channel(s). The device is particularly suited to the growth of cells mimicking dermal layers.

公开(公告)号：US10989721B2

公开(公告)日：2021-04-27

申请号：US15648162

申请日：2017-07-12

Applicant: Emulate Inc.

Inventor： Daniel Levner ,  Christopher David Hinojosa ,  Norman Wen ,  Jacob Fraser ,  Justin Nguyen ,  Riccardo Barrile ,  Geraldine Hamilton ,  Catherine Karalis ,  Hyoungshin Park ,  Antonio Varone ,  Andries Van der Meer ,  Monicah Otieno ,  David Conegliano

IPC: G01N33/86 ,  B01L3/00 ,  C12M3/06 ,  C12M1/00 ,  C12M1/42 ,  C12M1/34 ,  G01N33/543 ,  G01N33/80

Abstract: Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.

公开(公告)号：US10961496B2

公开(公告)日：2021-03-30

申请号：US15781370

申请日：2016-12-02

Applicant: EMULATE, INC.

Inventor： Daniel Levner ,  Christopher David Hinojosa ,  Norman Wen ,  Antonio Varone ,  Justin Nguyen ,  Lina Williamson ,  S. Jordan Kerns ,  Catherine Karalis ,  Geraldine Hamilton ,  Carol Lucchesi

IPC: C12M1/42 ,  C12M3/06 ,  C12M1/12 ,  G01N33/50 ,  G01N33/543 ,  C12M1/00 ,  C12N5/0793 ,  C12N5/079 ,  C12N5/071 ,  C12N5/077

Abstract: A microfluidic device is contemplated comprising an open-top cavity with structural anchors on the vertical wall surfaces that serve to prevent gel shrinkage-induced delamination, a porous membrane (optionally stretchable) positioned in the middle over a microfluidic channel(s). The device is particularly suited to the growth of cells mimicking dermal layers.

公开(公告)号：US20180015462A1

公开(公告)日：2018-01-18

申请号：US15648085

申请日：2017-07-12

Applicant: Emulate Inc. ,  JANSSEN BIOTECH, Inc

Inventor： Daniel Levner ,  Christopher David Hinojosa ,  Norman Wen ,  Jacob Fraser ,  Justin Nguyen ,  Riccardo Barrile ,  Geraldine Hamilton ,  Catherine Karalis ,  Hyoung Shin Park ,  Antonio Varone ,  Andries Van der Meer ,  Monica Otieno ,  David Conegliano

IPC: B01L3/00 ,  G01N33/86

CPC classification number: G01N33/86 ,  B01L3/5023 ,  B01L3/502707 ,  B01L3/502715 ,  B01L3/502746 ,  B01L3/502761 ,  B01L2200/02 ,  B01L2200/027 ,  B01L2200/0605 ,  B01L2200/0647 ,  B01L2200/16 ,  B01L2300/0809 ,  B01L2300/0816 ,  B01L2300/0867 ,  B01L2300/0883 ,  B01L2300/0887 ,  B01L2300/14 ,  B01L2300/16 ,  C12M23/16 ,  C12M29/00 ,  C12M29/04 ,  C12M29/10 ,  C12M35/08 ,  C12M41/46 ,  G01N33/54366 ,  G01N2500/10

Abstract: Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.

公开(公告)号：US20170285003A1

公开(公告)日：2017-10-05

申请号：US15474214

申请日：2017-03-30

Applicant: EMULATE, INC.

Inventor： Geraldine A. Hamilton ,  Norman Wen ,  Catherine Karalis ,  Antonio Varone ,  Daniel Levner ,  Riccardo Barrile

IPC: G01N33/50

CPC classification number: C12M23/16 ,  C12M21/00 ,  C12M25/02 ,  C12N5/0693 ,  G01N33/5011 ,  G01N33/5017

Abstract: The invention generally relates to a microfluidic platforms or “chips” for testing and understanding cancer, and, more specifically, for understanding the factors that contribute to cancer invading tissues and causing metastases. Tumor cells are grown on microfluidic devices with other non-cancerous tissues under conditions that simulate tumor invasion. The interaction with immune cells can be tested to inhibit this activity by linking a cancer chip to a lymph chip.

公开(公告)号：US20170226478A1

公开(公告)日：2017-08-10

申请号：US15458185

申请日：2017-03-14

Applicant: EMULATE, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Jordan Kerns ,  Norman Wen ,  Geraldine Hamilton ,  Christopher Hinojosa ,  Jacob Fraser ,  Catherine Karalis ,  Janna Nawroth ,  Dhruv Sareen ,  Anjoscha Kaus ,  Berhan Mandefro ,  Hyoung Shin Park ,  Ville Kujala

IPC: C12N5/0793 ,  B01L3/00 ,  C12N5/077

CPC classification number: C12N5/0619 ,  C12M23/16 ,  C12N5/0658 ,  C12N2502/083 ,  C12N2506/45 ,  C12N2531/00 ,  C12N2533/52

Abstract: The invention relates to culturing motor neuron cells together with skeletal muscle cells in a fluidic device under conditions whereby the interaction of these cells mimic the structure and function of the neuromuscular junction (NMJ) providing a NMJ-on-chip. Good viability, formation of myo-fibers and function of skeletal muscle cells on fluidic chips allow for measurements of muscle cell contractions. Embodiments of motor neurons co-cultures with contractile myo-fibers are contemplated for use with modeling diseases affecting NMJ's, e.g. Amyotrophic lateral sclerosis (ALS).

公开(公告)号：US20240309331A1

公开(公告)日：2024-09-19

申请号：US18591819

申请日：2024-02-29

Applicant: Emulate, Inc.

Inventor： S. Jordan Kerns ,  Catherine Karalis ,  Janna Nawroth ,  Remi Villenave ,  Jenifer Obrigewitch ,  Doris Roth ,  Michael Salmon ,  Athanasia Apostolou ,  David Conegliano

IPC: C12N5/071 ,  C12M1/42 ,  C12M3/06 ,  C12N1/20 ,  C12Q1/04

CPC classification number: C12N5/0679 ,  C12M23/16 ,  C12M35/04 ,  C12M35/08 ,  C12N1/20 ,  C12N5/0688 ,  C12Q1/04 ,  C12N2500/02 ,  C12N2502/70 ,  C12N2506/23 ,  C12N2537/00

Abstract: The present invention relates to a combination of microbes, cell culture systems and microfluidic fluidic systems for use in providing a human Intestine On-Chip with optimal intestinal motility. More specifically, in some embodiments, a microfluidic chip containing intestinal epithelial cells co-cultured with intestinal endothelial cells in the presence of bacteria, such as probiotic bacteria, may find use in providing an Intestine-On-Chip for testing intestinal motility function. In some embodiments, an Intestine On-Chip may be used for identifying (testing) therapeutic compounds continuing probiotic microbes or compounds for inducing intestinal motility for use in treating gastrointestinal disorders or diseases related to intestinal function.

公开(公告)号：US12036548B2

公开(公告)日：2024-07-16

申请号：US16997509

申请日：2020-08-19

Applicant: EMULATE, INC.

Inventor： Catherine Karalis ,  Ville Kujala

IPC: B01L3/00 ,  C12M3/06 ,  C12Q1/6809 ,  G01N33/50 ,  C12M1/12

CPC classification number: B01L3/5027 ,  C12M23/16 ,  C12Q1/6809 ,  G01N33/5023 ,  G01N33/5064 ,  G01N33/5091 ,  B01L2300/0819 ,  B01L2400/0487 ,  C12M25/02

Abstract: The present invention relates to microfluidic fluidic devices, methods and systems for use in identifying epigenetic signatures in a range of sample types, e.g., cells established on a “chip” (including but not limited to single cell samples, cell populations, C cell layers and whole tissues, such as a biopsy), immune cells, cfDNA, exosomes, and the like. More specifically, in some embodiments, a microfluidic chip containing a sample is contacted with a test compound (e.g. DNA altering test compound, an RNA expression altering test compound, etc.) for use in providing a diagnostic epigenetic signature for that type of sample (or cell type) exposed to that specific test compound. In some embodiments, after contact with a test compound, effluent fluids (e.g. fluids exiting the “chip” that contacted the cells) are derived for testing as a “virtual blood draw.” In some embodiments, epigenetic signatures include (but are not limited to) identifying specific combinations of modifications of chromosomes and specific modifications of DNA.

公开(公告)号：US11542476B2

公开(公告)日：2023-01-03

申请号：US16692383

申请日：2019-11-22

Applicant: EMULATE, INC.

Inventor： Remi Villenave ,  Carolina Lucchesi ,  Justin Nguyen ,  Catherine Karalis ,  Geraldine Hamilton ,  Buket Baddal ,  Michael Salmon

IPC: C12N5/071 ,  B01L3/00 ,  C12N1/20

Abstract: The present invention relates to microfluidic fluidic systems and methods for the in vitro modeling diseases of the lung and small airway. In one embodiment, the invention relates to a system for testing responses of a microfluidic Small Airway-on-Chip infected with one or more infectious agents (e.g. respiratory viruses) as a model of respiratory disease exacerbation (e.g. asthma exacerbation). In one embodiment, this disease model on a microfluidic chip allows for a) the testing of anti-inflammatory and/or anti-viral compounds introduced into the system, as well as b) the monitoring of the participation, recruitment and/or movement of immune cells, including the transmigration of cells. In particular, this system provides, in one embodiment, an in-vitro platform for modeling severe asthma as “Severe Asthma-on-Chip.” In some embodiments, this invention provides a model of viral-induced asthma in humans for use in identifying potentially effective treatments.